Analystreport

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $741.00 price target on the stock, up

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com